📣 VC round data is live. Check it out!
- Public Comps
- Genus
Genus Valuation Multiples
Discover Genus' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Presco, BGI Genomics, Austevoll Seafood, COSUMAR and more.
Genus Overview
About Genus
Genus PLC is an animal genetics company focused on improving cattle and pig populations to support sustainable food production. The company operates through two main business units: one providing bovine genetics mainly for dairy and beef cattle, and the other offering porcine genetics for pork production. Genus develops genetically superior breeding animals using scientific techniques. It generates revenue by selling genetics, including semen and embryos, as well as through related services under multi-year royalty agreements. The principal activities of each segment are: (a) Genus PIC porcine sales business, (b) Genus ABS: bovine sales business, and (c) Genus Research and Development: spending on research and development.
Founded
1994
HQ

Employees
3.3K
Website
Financials (LTM)
EV
$2B
Valuation Multiples
Start free trialGenus Financials
Genus reported last 12-month revenue of $910M and EBITDA of $180M.
In the same LTM period, Genus generated $363M in gross profit, $180M in EBITDA, and $89M in net income.
Revenue (LTM)
Genus P&L
In the most recent fiscal year, Genus reported revenue of $905M and EBITDA of $163M.
Genus is profitable as of last fiscal year, with gross margin of 30%, EBITDA margin of 18%, and net margin of 8%.
Financial data powered by Morningstar, Inc.
Genus Stock Performance
Genus has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Genus' stock price is $31.32.
Genus share price increased by 14.6% in the last year.
Genus has an EPS (earnings per share) of $1.09.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -0.0% | -0.0% | -2.7% | 14.6% | $1.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGenus Valuation Multiples
Genus trades at 2.6x EV/Revenue multiple, and 13.2x EV/EBITDA.
EV / Revenue (LTM)
Genus Financial Valuation Multiples
As of June 2, 2026, Genus has market cap of $2B and EV of $2B.
Genus has a P/E ratio of 23.4x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Genus Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Genus Margins & Growth Rates
Genus grew revenue by 1% and EBITDA by 11% in the last fiscal year.
In the most recent fiscal year, Genus reported gross margin of 30%, EBITDA margin of 18%, and net margin of 8%.
Genus Margins
Genus Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Genus Operational KPIs
Genus' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Genus' Rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Genus' Rule of X is 22% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Genus Competitors
Genus competitors include Presco, BGI Genomics, Austevoll Seafood, COSUMAR, Adecoagro, Premier Group, Braiin, UIE, Andersons and FMC.
Most Genus public comparables operate across Agriculture, Diagnostics & Genomics, Bioindustrials, BioTech, AgriTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 8.1x | 7.0x | 11.1x | 9.8x | |||
| 3.4x | 3.3x | 42.7x | 39.0x | |||
| 0.7x | 0.7x | 5.4x | 4.7x | |||
| 1.2x | 1.7x | 10.5x | 10.6x | |||
| 2.7x | 2.1x | 10.2x | 7.9x | |||
| 1.5x | 1.4x | 12.8x | 10.6x | |||
| 32.9x | - | (158.7x) | - | |||
| 2.6x | - | 4.6x | - | |||
This data is available for Pro users. Sign up to see all Genus competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Genus
Genus has acquired 1 company to date.
Last acquisition by Genus was on February 16th 2015. Genus acquired In Vitro Brasil for $7M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Genus
| Description | In Vitro Brasil is a Uberaba-headquartered biotechnology firm that leads bovine embryo production in Latin America through in-vitro fertilization techniques. The company transfers over 50,000 embryos annually to clients across Brazil and exports to countries including Argentina and Paraguay. Operating production labs in Minas Gerais, it supports genetic improvement programs for dairy and beef cattle breeds. In Vitro Brasil partners with major agribusinesses and research institutions to advance reproductive technologies, maintaining facilities equipped for oocyte collection, embryo culture, and cryopreservation. |
| HQ Country | |
| HQ City | São Paulo |
| Deal Date | 16 Feb 2015 |
| Valuation | $7M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Genus acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Genus
| When was Genus founded? | Genus was founded in 1994. |
| Where is Genus headquartered? | Genus is headquartered in United Kingdom. |
| How many employees does Genus have? | As of today, Genus has over 3K employees. |
| Who is the CEO of Genus? | Genus' CEO is Jorgen Kokke. |
| Is Genus publicly listed? | Yes, Genus is a public company listed on London Stock Exchange. |
| What is the stock symbol of Genus? | Genus trades under GNS ticker. |
| When did Genus go public? | Genus went public in 2000. |
| Who are competitors of Genus? | Genus main competitors include Presco, BGI Genomics, Austevoll Seafood, COSUMAR, Adecoagro, Premier Group, Braiin, UIE, Andersons, FMC. |
| What is the current market cap of Genus? | Genus' current market cap is $2B. |
| What is the current revenue of Genus? | Genus' last 12 months revenue is $910M. |
| What is the current revenue growth of Genus? | Genus revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Genus? | Current revenue multiple of Genus is 2.6x. |
| What is the current EBITDA of Genus? | Genus' last 12 months EBITDA is $180M. |
| What is Genus' EBITDA margin? | Genus' last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Genus? | Current EBITDA multiple of Genus is 13.2x. |
| What is the current FCF of Genus? | Genus' last 12 months FCF is $62M. |
| What is Genus' FCF margin? | Genus' last 12 months FCF margin is 7%. |
| What is the current EV/FCF multiple of Genus? | Current FCF multiple of Genus is 38.4x. |
| How many companies Genus has acquired to date? | As of June 2026, Genus has acquired 1 company. |
| What was the largest acquisition by Genus? | $7M acquisition of In Vitro Brasil on 16th February 2015 was the largest M&A Genus has done to date. |
| What companies Genus acquired? | Genus acquired In Vitro Brasil. |
| In how many companies Genus has invested to date? | Genus hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Genus
Lists including Genus
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
